Iowanews Headlines

Gastroesophageal Reflux Disease (GERD) Market to Grow Rapidly During the Forecast Period (2022-2032) – DelveInsight | Key Companies – Addpharma, Renexxion, HK inno.N, Phathom Pharma, Jiangsu Sindora

 Breaking News
  • No posts were found

Gastroesophageal Reflux Disease (GERD) Market to Grow Rapidly During the Forecast Period (2022-2032) – DelveInsight | Key Companies – Addpharma, Renexxion, HK inno.N, Phathom Pharma, Jiangsu Sindora

March 01
23:34 2023
Gastroesophageal Reflux Disease (GERD) Market to Grow Rapidly During the Forecast Period (2022-2032) - DelveInsight | Key Companies -  Addpharma, Renexxion, HK inno.N, Phathom Pharma, Jiangsu Sindora
DelveInsight Business Research LLP
As per DelveInsight, the Gastroesophageal Reflux Disease (GERD) Market is anticipated to grow immensely in the coming years owing to the rise in the number of prevalent cases of GERD patients, the rise in the healthcare spending across the world and the launch of the emerging therapies.

Key players, such as Phathom Pharmaceutical, Takeda, Sinorda Biomedicine, and others, are actively involved in developing drugs for Gastroesophageal reflux disease (GERD).

DelveInsight’s “Gastroesophageal Reflux Disease (GERD) Market Insights, Epidemiology, and Market Forecast 2032” report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Gastroesophageal Reflux Disease market size, share, trends, and growth opportunities in the seven major markets (7MM) (i.e., the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom and Japan).

The Gastroesophageal Reflux Disease market report covers emerging drugs, current treatment practices, market share of individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current treatment practice/algorithm, key drivers & barriers impacting the market growth, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market. 

Gastroesophageal Reflux Disease Market

Gastroesophageal Reflux Disease (GERD): An Overview

Gastroesophageal reflux disease (GERD) is a digestive disorder that occurs when acidic stomach juices, food, and fluids back up from the stomach into the esophagus. GERD is the regular, persistent, and long-term occurrence of GER.

GERD is caused by multiple different mechanisms that can be intrinsic, structural, or both, leading to the disruption of the esophagogastric junction barrier resulting in exposure of the esophagus to acidic gastric contents. The typical clinical presentation of GERD is heartburn and regurgitation. However, GERD can also present with other symptoms, including dysphagia, odynophagia, belching, epigastric pain, and nausea.

Risk factors for GERD include older age, excessive body mass index (BMI), smoking, anxiety/depression, and less physical activity at work. Eating habits may also contribute to GERD, including the acidity of food and the size and timing of meals, particularly concerning sleep.

Gastroesophageal Reflux Disease (GERD) Market Key Facts

  • As per Marco G Patti (2020), 25%-40% of Americans experience symptomatic GERD at some point, and about 7%-10% of Americans experience symptoms of GERD on a daily basis. Many individuals control their symptoms with over-the-counter (OTC) medications, and without consulting a medical professional, the actual number of individuals with GERD is probably higher.

  • As per Jorabar Singh Nirwan et al. (2020), GERD’s global prevalence was 13.98%, and 4.16% in China. Using the United Nations 2017 Revision of World Population Prospects, the estimated number of individuals suffering from GORD globally is 1.03 billion.

  • As per Wang et al. (2019), the prevalence of GERD (RE and NERD) was 17.3%, which was much higher in the ESCC population than 2.3% to 5.2% reported in the general Chinese population. 

Gastroesophageal Reflux Disease (GERD) Market

The market outlook section of the report helps to build a detailed comprehension of the historical, current and forecasted Gastroesophageal Reflux Disease market size by analyzing the impact of current and emerging pipeline therapies. It also thoroughly assesses the market drivers & barriers, unmet needs, and emerging technologies set to impact the market dynamics.

The report gives complete detail of the Gastroesophageal Reflux Disease market trend for each marketed drug and mid & late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, their Mechanism of Action (MOA), Route of Administration (ROA), molecule types, competition with other therapies, brand value, and their impact on the market.

Gastroesophageal Reflux Disease (GERD) Epidemiology Assessment 

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted epidemiology trends by exploring numerous studies and research. The epidemiology section also provides a detailed analysis of diagnosed and prevalent patient pool, future trends, and views of key opinion leaders. 

The Report Covers the Gastroesophageal Reflux Disease (GERD) Epidemiology, Segmented as –

  • Prevalent Cases of Gastroesophageal reflux disease (GERD) in the 7MM [2019–2032]

  • Diagnosed Cases of Gastroesophageal reflux disease (GERD) in the 7MM [2019–2032]

  • Treated Cases of Gastroesophageal reflux disease (GERD) in the 7MM [2019–2032]

  • Age-specific Prevalent Cases of Gastroesophageal reflux disease (GERD) in the 7MM [2019–2032]

  • Gender-specific Prevalent Cases of Gastroesophageal reflux disease (GERD) in the 7MM [2019–2032]

Gastroesophageal Reflux Disease (GERD) Drugs Uptake and Pipeline Development Activities

The drug uptake section focuses on the uptake rate of potential drugs recently launched in the Gastroesophageal Reflux Disease market or expected to be launched during the study period. The analysis covers the Gastroesophageal Reflux Disease market uptake by drugs, patient uptake by therapies, and sales of each drug. Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Gastroesophageal Reflux Disease pipeline development activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyses recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Learn How the Gastroesophageal Reflux Disease Market Will Evolve and Grow by 2032 @ 

Gastroesophageal Reflux Disease (GERD) Therapeutics Analysis

Several major pharma and biotech giants are developing therapies for Gastroesophageal Reflux Disease (GERD). Currently, Daewoong Pharmaceutical is leading the therapeutics market with its Gastroesophageal Reflux Disease (GERD) drug candidates in the most advanced stage of clinical development.

The Leading Companies in the Gastroesophageal Reflux Disease (GERD) Therapeutics Market Include:

  • Addpharma

  • Chong Kun Dang Pharmaceutical

  • Cinclus Pharma

  • Daewoong Pharmaceutical

  • HK inno.N Corporation

  • Jeil Pharmaceutical

  • Jiangsu Sindora Biomedicine

  • Phathom Pharmaceuticals

  • Renexxion

  • Takeda

  • Trio Medicines

And Many Others

Emerging and Marketed Drugs in the Gastroesophageal Reflux Disease Therapeutics Market Include:

  • AD-214: Addpharma

  • Fexuprazan: Daewoong Pharmaceutical

  • IN-C002: HK inno.N

  • IN-C003: HK inno.N

  • JP-1366: Jeil Pharmaceuticals

  • Naronapride: Renexxion

  • Vonoprazan: Phathom Pharmaceuticals

  • X842: Jiangsu Sindora Biomedicine

And Many More

The Report Covers the In-depth Assessment of the Emerging Drugs & Key Companies. Download the Sample Report to Learn More @

Table of Content (TOC)

1. Key Insights

2. Executive Summary 

3. Gastroesophageal Reflux Disease Competitive Intelligence Analysis

4. Gastroesophageal Reflux Disease Market Overview at a Glance

5. Gastroesophageal Reflux Disease Disease Background and Overview

6. Gastroesophageal Reflux Disease Patient Journey

7. Gastroesophageal Reflux Disease Epidemiology and Patient Population (In the US, EU5, and Japan)

8. Gastroesophageal Reflux Disease Treatment Algorithm, Current Treatment, and Medical Practices

9. Gastroesophageal Reflux Disease Unmet Needs

10. Key Endpoints of Gastroesophageal Reflux Disease Treatment

11. Gastroesophageal Reflux Disease Marketed Products

12. Gastroesophageal Reflux Disease Emerging Drugs and Latest Therapeutic Advances

13. Gastroesophageal Reflux Disease Seven Major Market Analysis

14. Attribute Analysis

15. Gastroesophageal Reflux Disease Market Outlook (In US, EU5, and Japan)

16. Gastroesophageal Reflux Disease Access and Reimbursement Overview

17. KOL Views on the Gastroesophageal Reflux Disease Market

18. Gastroesophageal Reflux Disease Market Drivers

19. Gastroesophageal Reflux Disease Market Barriers

20. Appendix

21. DelveInsight Capabilities

22. Disclaimer

*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.

Download the Sample PDF to Learn More About the Key Offerings of the Report @


Take control of your pharmaceutical portfolio with DelveInsight’s comprehensive consulting services. Get in touch and discover how we can help you manage your pharmaceutical portfolio today @ Pharmaceutical Portfolio Management Services 

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States